<?xml version="1.0" encoding="UTF-8"?>
<p>In comparison with other biologic agents, RTX has been associated with high HBVr rates also in patients with resolved HBV infection.
 <sup>
  <xref rid="bibr63-1759720X20912646" ref-type="bibr">63</xref>,
  <xref rid="bibr67-1759720X20912646" ref-type="bibr">67</xref>
  <xref rid="bibr68-1759720X20912646" ref-type="bibr"/>
  <xref rid="bibr69-1759720X20912646" ref-type="bibr"/>
  <xref rid="bibr70-1759720X20912646" ref-type="bibr"/>–
  <xref rid="bibr71-1759720X20912646" ref-type="bibr">71</xref>
 </sup> In their technical review, which supported the AGA guidelines, Perrillo and colleagues calculated a pooled baseline risk estimate of HBVr at 16.9% in this group of patients, which was based on hematology/oncology studies.
 <sup>
  <xref rid="bibr17-1759720X20912646" ref-type="bibr">17</xref>
 </sup> However, in prospective or retrospective studies with patients suffering with rheumatic diseases, the rate of HBVr under RTX therapy was much lower (6/266 patients or 2%).
 <sup>
  <xref rid="bibr58-1759720X20912646" ref-type="bibr">58</xref>,
  <xref rid="bibr72-1759720X20912646" ref-type="bibr">72</xref>
  <xref rid="bibr73-1759720X20912646" ref-type="bibr"/>
  <xref rid="bibr74-1759720X20912646" ref-type="bibr"/>
  <xref rid="bibr75-1759720X20912646" ref-type="bibr"/>–
  <xref rid="bibr76-1759720X20912646" ref-type="bibr">76</xref>
 </sup> Interestingly, the majority of reported patients with HBVr (4/6) came from a high-incidence HBV country (Taiwan).
 <sup>
  <xref rid="bibr76-1759720X20912646" ref-type="bibr">76</xref>
 </sup>
</p>
